Ciladopa (AY-27,110) je dopaminski agonist sa sličnom hemijskom strukturom sa dopaminom.[4] On je bio ispitivan kao mogući antiparkinsonski agens, ali su dalja ispitivanja prekinuta zbog moguće tumorogeneze.[5][6][7][8]
Ciladopa
|
| (IUPAC) ime
|
| 24-[(2S)-2-(3,4-dimetoksifenil)-2-hidroksietil]piperazin-1-il}ciklohepta-2,4,6-trien-1-on
|
| Klinički podaci
|
| Identifikatori
|
| CAS broj
|
80109-27-9
|
| ATC kod
|
nije dodeljen
|
| PubChem[1][2]
|
133371
|
| ChemSpider[3]
|
117659
|
| UNII
|
D09L486R3J  Y
|
| Hemijski podaci
|
| Formula
|
C21H26N2O4
|
| Mol. masa
|
370,44 g/mol
|
| SMILES
|
eMolekuli & PubHem
|
| InChI |
|---|
InChI=1S/C21H26N2O4/c1-26-20-9-8-16(14-21(20)27-2)19(25)15-22-10-12-23(13-11-22)17-6-4-3-5-7-18(17)24/h3-9,14,19,25H,10-13,15H2,1-2H3/t19-/m1/s1 Y
Key: SGEKLKJQLHJVDK-LJQANCHMSA-N Y |
|
| Farmakoinformacioni podaci
|
| Trudnoća
|
?
|
| Pravni status
|
nije kontrolisana supstanca
|
| Način primene
|
Oralno
|
- ↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
- ↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
- ↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit
- ↑ Voith K (1985). „The comparative long-term effects of ciladopa (AY-27,110), a chemically novel dopaminergic agonist, in 6-OHDA-lesioned and intact rats”. Psychopharmacology 85 (4): 405–9. DOI:10.1007/BF00429654. PMID 3927334.
- ↑ Koller WC, Fields JZ, Gordon JH, Perlow MJ (September 1986). „Evaluation of ciladopa hydrochloride as a potential anti-Parkinson drug”. Neuropharmacology 25 (9): 973–9. DOI:10.1016/0028-3908(86)90190-5. PMID 3774130.
- ↑ Weiner WJ, Factor SA, Sanchez-Ramos J, Berger J (1987). „A double-blind evaluation of ciladopa in Parkinson's disease”. Movement Disorders : Official Journal of the Movement Disorder Society 2 (3): 211–7. DOI:10.1002/mds.870020308. PMID 3332914.
- ↑ Lieberman A, Gopinathan G, Neophytides A, Pasternack P, Goldstein M (May 1987). „Advanced Parkinson's disease: use of partial dopamine agonist, ciladopa”. Neurology 37 (5): 863–5. PMID 3574692.
- ↑ Lang AE (August 1987). „Update on dopamine agonists in Parkinson's disease: "beyond bromocriptine"”. The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques 14 (3 Suppl): 474–82. PMID 3315148.
